AOTMiT: Transparency Council on heart failure and chronic kidney disease, among others

Agenda

1. Prepare a position paper on the evaluation of the drug Jardiance (empagliflozinum) for the indication:
   
   • Chronic kidney disease in adult patients:
     • With eGFR in the range of ≥20 ml/min/1.73 m² to <45 ml/min/1.73 m², taking ACEi/ARB-based therapy for at least 4 weeks or with a contraindication to such therapy.
     • With an eGFR of ≥45 ml/min/1.73 m² to <90 ml/min/1.73 m² and albuminuria or proteinuria, taking ACEi/ARB-based therapy for at least 4 weeks or with a contraindication to such therapy.

1. Prepare a position paper on the evaluation of the drug Jar...

   Content locked

   To gain access to the complete English section of the Medexpress.pl, kindly reach out to us at [email protected].

   If you already have an account, please log in